Talphera Reports Third Quarter 2025 Financial Results and Corporate Developments Talphera, Inc. announces its financial results for Q3 2025, highlighting key developments, including a $17 million financing and NEPHRO clinical study progress.

Talphera Reports Third Quarter 2025 Financial Results and Corporate Developments #United_States #San_Mateo #Talphera #Niyad #CorMedix

Talphera Secures $29 Million Through Strategic Private Placement Financing with CorMedix and Institutional Investors Talphera Inc. announces a major financing deal potentially totaling $29 million, with CorMedix as a key investor, aimed at advancing its innovative medical therapies.

Talphera Secures $29 Million Through Strategic Private Placement Financing with CorMedix and Institutional Investors #USA #San_Mateo #Talphera #NEPHRO_CRRT #CorMedix

Deerfield Management Confirms Successful Sale of Melinta Therapeutics to CorMedix, Inc. Deerfield Management Company has successfully finalized the sale of Melinta Therapeutics to CorMedix, highlighting a remarkable turnaround and growth strategy.

Deerfield Management Confirms Successful Sale of Melinta Therapeutics to CorMedix, Inc. #USA #New_York #Deerfield_Management #Melinta_Therapeutics #CorMedix

#CRMD shares soar 18% as DefenCath expands its reach with a major dialysis provider, now set to treat 50% more patients than expected. The company also raised its Q2 sales outlook to $35–$40M, signaling accelerating demand and commercial momentum.
#CorMedix
prismmarketview.com/cormedix-sha...